Century Therapeutics (NASDAQ:IPSC) Price Target Lowered to $7.00 at Chardan Capital

Century Therapeutics (NASDAQ:IPSC) had its target price decreased by Chardan Capital from $11.00 to $7.00 in a report released on Monday morning,Benzinga reports. Chardan Capital currently has a buy rating on the stock.

A number of other research analysts have also weighed in on the company. Guggenheim dropped their target price on Century Therapeutics from $12.00 to $5.00 and set a “buy” rating on the stock in a report on Friday. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Century Therapeutics in a report on Wednesday, January 22nd. Finally, Piper Sandler reduced their target price on shares of Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating for the company in a research note on Thursday, March 20th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $5.00.

Century Therapeutics Stock Up 5.2 %

Shares of IPSC opened at $0.58 on Monday. The business’s fifty day moving average is $0.74 and its 200 day moving average is $1.15. Century Therapeutics has a 12-month low of $0.52 and a 12-month high of $4.50. The stock has a market cap of $49.63 million, a P/E ratio of -0.32 and a beta of 1.75.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.02. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. The firm had revenue of $4.18 million during the quarter, compared to analysts’ expectations of $0.67 million. On average, analysts expect that Century Therapeutics will post -1.61 EPS for the current year.

Hedge Funds Weigh In On Century Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in IPSC. Marshall Wace LLP purchased a new stake in Century Therapeutics during the fourth quarter worth about $36,000. Jane Street Group LLC raised its holdings in shares of Century Therapeutics by 166.2% in the 4th quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock worth $49,000 after purchasing an additional 29,992 shares during the period. Two Sigma Advisers LP bought a new stake in shares of Century Therapeutics in the 4th quarter worth approximately $52,000. Sei Investments Co. bought a new position in Century Therapeutics during the fourth quarter valued at $53,000. Finally, Two Sigma Investments LP purchased a new stake in Century Therapeutics in the fourth quarter worth $67,000. 50.20% of the stock is owned by hedge funds and other institutional investors.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.